0001104659-21-121301.txt : 20210930 0001104659-21-121301.hdr.sgml : 20210930 20210930171321 ACCESSION NUMBER: 0001104659-21-121301 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210930 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210930 DATE AS OF CHANGE: 20210930 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Transcode Therapeutics, Inc. CENTRAL INDEX KEY: 0001829635 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811065054 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40363 FILM NUMBER: 211295792 BUSINESS ADDRESS: STREET 1: 6 LIBERTY SQUARE STREET 2: #2382 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-301-6857 MAIL ADDRESS: STREET 1: 6 LIBERTY SQUARE STREET 2: #2382 CITY: BOSTON STATE: MA ZIP: 02109 8-K 1 tm2128877d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2021

TRANSCODE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40363

81-1065054

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

TransCode Therapeutics, Inc.

6 Liberty Square, #2382

Boston, Massachusetts 02109

(Address of principal executive offices, including zip code)

(857) 837-3099

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered or to be registered pursuant to Section 12(b) of the Act.

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		RNAZ		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01

Other Information.

On September 30, 2021, TransCode Therapeutics, Inc. (the “Company”) issued a press release to announce the appointment of Zdravka Medarova, Ph.D. as the Company’s Chief Technology Officer, effective October 1, 2021. A copy of the press release is filed herewith as Exhibit 99.1 to this Report on Form 8-K, and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

99.1		Press release of TransCode Therapeutics, Inc., dated September 30, 2021.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TransCode Therapeutics, Inc.

Date: September 30, 2021	By:	/s/ Thomas A. Fitzgerald
		Thomas A. Fitzgerald
		Chief Financial Officer

EX-99.1 2 tm2128877d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer

Boston, MA, Sept. 30, 2021 – TransCode Therapeutics, Inc. (TransCode) (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today announced that Zdravka Medarova, Ph.D., has been appointed as the company’s Chief Technology Officer effective October 1, 2021. Dr. Medarova is a scientific co-founder of TransCode and has served as a member of TransCode’s advisory board since its founding in January 2016.

“We are delighted to welcome Zdravka as a full-time member of the TransCode team,” said Michael Dudley, CEO of TransCode. “We have long benefitted from her extensive expertise in developing nanotechnology and imaging tools to better understand cancer initiation and progression, as well as her support of our preclinical research through affiliations with Harvard Medical School and Massachusetts General Hospital. Zdravka’s leadership will be invaluable as we pursue validation of our TTX platform as a viable means to bring the promise of RNA therapeutics to the treatment of cancer.”

Dr. Medarova joins TransCode from Harvard Medical School and Massachusetts General Hospital (MGH), where she served as an Associate Professor of Radiology at Harvard Medical School and an Assistant in Neuroimaging at the Athinoula A. Martinos Center for Biomedical Imaging at MGH. Dr. Medarova carried out seminal work in the field of RNA oncology. Together with her colleagues at MGH, she described, for the first time, the design and application of iron oxide nanoparticles as imaging-capable carriers of siRNA to tumors. This work generated substantial interest in the research community since it illustrated the value of these nanoparticles for delivering small RNA therapy for oncology applications and described an approach for the noninvasive monitoring of RNA delivery. Since then, Dr. Medarova has emerged as one of the leaders in the field of non-coding RNA delivery to cancer. She has developed a robust NIH funded program and authored multiple high-impact publications on the topic of RNA delivery, nanotechnology, and the biology of cancer metastasis.

Dr. Medrova obtained a B.A. in pre-medicine from the University of Southerin Maine and a Ph.D. in Genetics from the University of New Hamspshire.

“As one of TransCode’s scientific co-founders, in addition to supporting the company as a researcher and advisor, I have had significant exposure to the company’s TTX delivery platform and lead candidate, TTX-MC138,” said Dr. Medarova. “Across this experience, I believe TransCode’s approach may finally solve the persistent challenge of RNA delivery in oncology with the potential for tremendous patient impact. I am eager to join TransCode at this important time in the company’s growth, with first-in-human studies and clinical assessment on the horizon, to help bring TransCode’s technology to its fullest potential.”

Dr. Medarova has been invited to present at the upcoming International Oligonucleotide and Peptide Conference (IOPC) on October 18-19, 2021. Her talk, “The Future of Oncology Through the Lens of RNA,” will support TransCode’s approach to RNA delivery using its TTX platform technology.

About TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company’s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the therapeutic potential of TTX-MC138 and statements concerning TransCode’s development programs and TTX technology platform generally. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk associated with drug discovery and development; the risk that the results of our planned clinical trials will not be consistent with our pre-clinical studies or expectations; risks associated with the timing and outcome of TransCode's planned regulatory submissions; risks associated with TransCode’s planned clinical trials for its product candidates; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risks associated with TransCode’s financial condition and its need to obtain additional funding to support its business activities, including TransCode’s ability to continue as a going concern; risks associated with TransCode’s dependence on third parties; and risks associated with the COVID-19 coronavirus. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode’s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled “Risk Factors” in TransCode’s Quarterly Report on Form 10-Q for the period ended June 30, 2021, as well as discussions of potential risks, uncertainties and other important factors in TransCode’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release; TransCode undertakes no duty to update this information unless required by law.

Investor Contact:

Josh Rappaport

Stern Investor Relations

josh.rappaport@sternir.com

Company Contact:
Tom Fitzgerald, CFO
tom.fitzgerald@transcodetherapeutics.com

EX-101.SCH 3 rnaz-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 rnaz-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 rnaz-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 tm2128877d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001829635 2021-09-30 2021-09-30 iso4217:USD shares iso4217:USD shares 0001829635 false 8-K 2021-09-30 TRANSCODE THERAPEUTICS, INC. DE 001-40363 81-1065054 TransCode Therapeutics, Inc. 6 Liberty Square #2382 Boston MA 02109 857 837-3099 false false false false Common Stock, par value $0.0001 per share RNAZ NASDAQ true false XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Sep. 30, 2021
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Sep. 30, 2021
Entity File Number	001-40363
Entity Registrant Name	TRANSCODE THERAPEUTICS, INC.
Entity Central Index Key	0001829635
Entity Tax Identification Number	81-1065054
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	TransCode Therapeutics, Inc.
Entity Address, Address Line Two	6 Liberty Square
Entity Address, Address Line Three	#2382
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02109
City Area Code	857
Local Phone Number	837-3099
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	RNAZ
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://transcodetherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2128877d1_8k.htm rnaz-20210930.xsd rnaz-20210930_lab.xml rnaz-20210930_pre.xml tm2128877d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2128877d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2128877d1_8k.htm" ] }, "labelLink": { "local": [ "rnaz-20210930_lab.xml" ] }, "presentationLink": { "local": [ "rnaz-20210930_pre.xml" ] }, "schema": { "local": [ "rnaz-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rnaz", "nsuri": "http://transcodetherapeutics.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2128877d1_8k.htm", "contextRef": "From2021-09-30to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://transcodetherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2128877d1_8k.htm", "contextRef": "From2021-09-30to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://transcodetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001104659-21-121301-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-121301-xbrl.zip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